Floatz logo

Zofran

Non-Hodgkin's Lymphoma

MEI Pharma, Inc.Phase 3Active
BB
71/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
70/ 100
Competitive Position
73/ 100

Competitive context

46 Active assets in the Non-Hodgkin's Lymphoma cohort.

Asset / SponsorPhaseRating
Inno-206
National Cancer Institute (NCI)
Phase 4BBB
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER
National Cancer Institute (NCI)
Phase 4BBB
Cyclophosphamide
National Cancer Institute (NCI)
Phase 4BBB
PREDNISONE TABLETS
National Cancer Institute (NCI)
Phase 3BBB
FILGRASTIM
Thomas Jefferson University
Phase 4BB

View all 50 →

Same molecule, other indications

Zofran is also rated in:

VomitingDormant
BBB
Indicative ·
73 / 100
View asset →
NauseaDormant
BBB
Indicative ·
73 / 100
View asset →
cancer of unknown primary siteDormant
BB
Indicative ·
71 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →